Skip to main content
OpenTrials

Clinical trial condition

Refractory Acute Myeloid Leukemia

Explore clinical trials studying Refractory Acute Myeloid Leukemia. Study availability and eligibility vary by location and protocol.

103 public trials 43 recruiting studies
Refine in advanced search Browse all conditions

Refractory Acute Myeloid Leukemia trial results

Active, not recruiting

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT04898894

Conditions
Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Hematologic Diseases, +14 more
Locations
  • Rady Children's Hospital-San Diego San Diego, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan-Kettering Cancer Center New York, United States
  • Childrens Hospital of Philadelphia Philadelphia, Pennsylvania, United States
View Trial Details
Active, not recruiting

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

NCT04203316

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +6 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center Denver, Colorado, United States
View all 28 locations
View Trial Details
Active, not recruiting

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

NCT04891757

Conditions
Advanced Hematologic Malignancy, Bone Marrow Diseases, Chronic Disease, +19 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Vanderbilt University Medical Center Nashville, Tennessee, United States
View Trial Details
Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

NCT02220985

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, +57 more
Locations
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details

Related conditions